Saturday, 10 October 2026European Markets

JUST EAT TAKEAWAY Stock Was 9.48% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with JUST EAT TAKEAWAY (TKWY.AS) rising 9.48% to €11.90 on Wednesday, following the last session's upward trend. AEX-Index jumped 1.39% to €920.62, following the last session's upward trend on what was an all-around up trend trading session today.

JUST EAT TAKEAWAY's last close was €10.87, 34.08% under its 52-week high of €16.49.

About JUST EAT TAKEAWAY

Just Eat Takeaway.com N.V. operates as an online food delivery company worldwide. Its marketplace connects consumers and restaurants through its platforms. The company was founded in 2000 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, JUST EAT TAKEAWAY has a trailing twelve months EPS of €-8.69.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -26.5%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 7.2%, now sitting on 5.17B for the twelve trailing months.

More news about JUST EAT TAKEAWAY (TKWY.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com